Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 686.

https://doi.org/10.1182/blood-2019-131981

Published: 2019

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 1793.

https://doi.org/10.1182/blood-2019-126828

Published: 2019

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

https://doi.org/10.1182/blood-2019-124191

Published: 2019

Journal Articles

Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial

Paola Neri, MD PhD, Ranjan Maity, PhD, Jonathan J Keats, PhD, Ines Tagoug, PhD, Justin Simms, Daniel Auclair, PhD, Sagar Lonial, MD FACP, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 120.

https://doi.org/10.1182/blood.V128.22.120.120

Published: 2016

Journal Articles

Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival

Victor Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Jason Tay, MDFRCPC MSc, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 2263.

https://doi.org/10.1182/blood.V128.22.2263.2263

Published: 2016

Journal Articles

High-Risk Cytogenetics Multiple Myeloma: Impact of Consolidation and Maintenance

Victor Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Jason Tay, MDFRCPC MSc, Fariborz Rashid-Kolvear, PhD, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 2271.

https://doi.org/10.1182/blood.V128.22.2271.2271

Published: 2016

Journal Articles

Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT

Victor Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Jason Tay, MDFRCPC MSc, Joanne Luider, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 2273.

https://doi.org/10.1182/blood.V128.22.2273.2273

Published: 2016

Journal Articles

IKZF1 Regulates BRD4 Retention and Recruitement at Enhancer in Myeloma Cells: Role of BRD4 in IMiDs Resistance

Paola Neri, MD PhD, Ines Tagoug, PhD, Ranjan Maity, PhD, Jacquelyn Babich, Lindsay Lockwood, Jonathan J Keats, PhD, Larry H Boise, PhD, Leif Bergsagel, MD, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 358.

https://doi.org/10.1182/blood.V128.22.358.358

Published: 2016

Journal Articles

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada

Hatem Alahwal, MPH, MBBS, Kevin W. Song, MD, Peter Duggan, MD, Heather J. Sutherland, MD PhD, Paola Neri, MD PhD, Raewyn Broady, MBChB, Nizar J. Bahlis, MD, Victor Jimenez-Zepeda, MD

Blood (2016) 128 (22): 2131.

https://doi.org/10.1182/blood.V128.22.2131.2131

Published: 2016

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma

Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Peter Duggan, MD, Rafael Alonso, MD, Juan José Lahuerta, MD PhD, Antonio Valeri, Paola Neri, MD PhD, Jason Tay, MD FRCPC MSc, Joaquin Martinez-Lopez

Blood (2016) 128 (22): 4505.

https://doi.org/10.1182/blood.V128.22.4505.4505

Published: 2016

Journal Articles

Early Relapse Following ASCT for Patients with MM: Identification of Predictor Factors in the Era of Novel Agents

Victor Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Jason Tay, MD FRCPC MSc, Joanne Luider, Fariborz Rashid-Kolvear, PhD, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 5818.

https://doi.org/10.1182/blood.V128.22.5818.5818

Published: 2016

Journal Articles

Ikaros-Dependent Downregulation of MYC with IMiDs in Myeloma (MM) Cells Is Mediated through the Depletion of the Acetylated Chromatin Reader BRD4 at Super-Enhancer Loci

Paola Neri, MD PhD, Ines Tagoug, PhD, Justin Simms, Ranjan Maity, PhD, Jacquelyn Babich, Victor Jimenez-Zepeda, MD, Peter Duggan, MD, Fariborz Kolvear, PhD, Jonathan J Keats, PhD, Leif Bergsagel, MD PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 4175.

https://doi.org/10.1182/blood.V126.23.4175.4175

Published: 2015

Journal Articles

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Christopher P. Venner, MD, Nizar J Bahlis, MD, Paola Neri, MD PhD, Irwindeep Sandhu, MD, Peter Duggan, MD, Andrew Belch, MD, Joanne D Hewitt, RN, BSN, NP, Linda M. Pilarski, PhD, Tatiana Nikitina, Victor H Jimenez-Zepeda, MD

Blood (2015) 126 (23): 4261.

https://doi.org/10.1182/blood.V126.23.4261.4261

Published: 2015

Journal Articles

Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Marcia Culham, RN, BSN, NP, Joanne Luider, Fariborz Rashid-Kolvear, PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 3189.

https://doi.org/10.1182/blood.V126.23.3189.3189

Published: 2015

Journal Articles

Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile

Michael D. Amatangelo, PhD, Paola Neri, MD PhD, Maria Ortiz, PhD, Chad C. Bjorklund, Anita K. Gandhi, PhD, Anke Klippel, Nizar J Bahlis, MD, Tom Daniel, Rajesh Chopra, MBBS, PhD, Matthew Trotter, Anjan Thakurta

Blood (2015) 126 (23): 1789.

https://doi.org/10.1182/blood.V126.23.1789.1789

Published: 2015

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Victor H Jimenez-Zepeda, MD, Christopher P. Venner, MD, Andrew Belch, Irwindeep Sandhu, MD, Tatiana Nikitina, Joanne D Hewitt, RN, BSN, NP, Peter Duggan, MD, Paola Neri, MD PhD, Fariborz Rashid-Kolvear, PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 1845.

https://doi.org/10.1182/blood.V126.23.1845.1845

Published: 2015

Journal Articles

Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 1846.

https://doi.org/10.1182/blood.V126.23.1846.1846

Published: 2015

Journal Articles

Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Joanne Luider, Nizar J Bahlis, MD

Blood (2015) 126 (23): 5492.

https://doi.org/10.1182/blood.V126.23.5492.5492

Published: 2015

Journal Articles

Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

Blood (2015) 126 (23): 5384.

https://doi.org/10.1182/blood.V126.23.5384.5384

Published: 2015

NARROW

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial

Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival

High-Risk Cytogenetics Multiple Myeloma: Impact of Consolidation and Maintenance

Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT

IKZF1 Regulates BRD4 Retention and Recruitement at Enhancer in Myeloma Cells: Role of BRD4 in IMiDs Resistance

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma

Early Relapse Following ASCT for Patients with MM: Identification of Predictor Factors in the Era of Novel Agents

Ikaros-Dependent Downregulation of MYC with IMiDs in Myeloma (MM) Cells Is Mediated through the Depletion of the Acetylated Chromatin Reader BRD4 at Super-Enhancer Loci

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience

Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only